Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica

Page 1 of about 3 results

ea0047oc6 | Spotlight on Neuroendocrine tumours | Theranostics2016

DNA damage assay in blood lymphocytes in peptide receptor radionuclide therapy patients with personalised high activities

Eberlein Uta , Scherthan Harry , Werner Rudolph A , Lapa Constantin , Bluemel Christina , Peper Michel , Buck Andreas K , Port Matthias , Lassmann Michael

Objectives: Radiation induces DNA double strand breaks (DSBs) that can be visualized and enumerated as microscopic γ-H2AX and 53BP1 foci. This study analysed the dose- and time-dependency of the DNA damage in blood lymphocytes in patients after a personalised high-activity 177Lu-DOTATATE treatment.Methods: We investigated multiple blood samples of three patients up to 96 h after personalised high-activity peptide receptor radionuclid...
0 shares

ea0047oc14 | Spotlight on Neuroendocrine tumours | Theranostics2016

68Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors – a head-to-head comparison with DOTATOC and FDG PET/CT

Lassmann Michael , Werner Rudolf A. , Weich Alexander , Wester Hans-Juergen , Scheurlen Michael , Higuchi Takahiro , Samnick Samuel , Bluemel Christina , Rudelius Martina , Buck Andreas K. , Lapa Constantin , Herrmann Ken

Introduction: Diagnostic imaging of neuroendocrine tumors (NETs) is the domain of somatostatin receptor (SSTR) agonists as well as FDG PET/CT in dedifferentiated tumors. SSTR also serves as target for receptor directed peptide therapy. More recently, specific ligands targeting the chemokine receptor 4 (CXCR4) were introduced potentially offering an additional theranostic option in NETs. Here we evaluated the CXCR4 expression using 68Ga-Pentixafor PET/CT in NET patie...
1 shares

ea0037oc1.3 | Adrenal 1 | ECE2015

[123/131I] azetidinylamide a novel radiotracer for diagnosis and treatment of adrenocortical tumours -- from bench to bedside

Hahner Stefanie , Heinze Britta , Herrmann Ken , Buck Andreas K , Blumel Christina , Hanscheid Heribert , Brumberg Joachim , Michelmann David , Nannen Lukas , Ries Martin , Fassnacht Martin , Allolio Bruno , Schirbel Andreas

Background: We have recently introduced [123/131I]iodometomidate (IMTO) which selectively binds to the adrenocortical enzymes aldosterone synthase and 11ß-hydroxylase as SPECT tracer. IMTO has been proven to be useful for molecular adrenal imaging and radiotherapy in adrenal cancer (ACC). As IMTO is rapidly inactivated by endogenous esterases which may impair target tissue to background activity and therapeutic efficacy, >50 new IMTO derivatives have been d...
0 shares

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more